NeuroOne Medical appoints Jason Mills to board of directors

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) appointed Jason Mills to its board of directors, effective December 18, 2025, according to a company statement.

Mills currently serves as executive vice president of strategy at Penumbra Inc. (NYSE: PEN), where he leads long-range planning, financial planning and analysis, business development, and investor relations. Penumbra develops technologies for medical conditions including ischemic stroke, venous thromboembolism, and acute limb ischemia.

Before joining Penumbra, Mills worked as a medical technology investment analyst for more than 20 years. He served as managing director and head of the medical technology equity research practice at Canaccord Genuity for over 13 years, where he prepared financial models, published research, and conducted due diligence on public and private companies in the sector.

Mills received recognition for his equity research work, ranking as the number two medical devices analyst in The Wall Street Journal's 2011 Best on the Street Survey and number one in the medical products segment of Forbes' 2010 Best Brokerage Analysts. He holds a bachelor's degree in economics from Yale University and a master's degree in sports administration from Ohio University.

At NeuroOne, Mills will serve on the compensation and nominating and corporate governance committees. The company develops minimally invasive solutions for EEG recording, monitoring, ablation, drug delivery and stimulation for patients with epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain, and other neurological disorders.

You May Also Be Interested In